The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils

Mucosal Immunology

Volumn 9, Issue 2, 2016, Pages 322-335

  Driss, V ^a   El Nady, M ^a,b   Delbeke, M ^a   Rousseaux, C ^c   Dubuquoy, C ^c   Sarazin, A ^a   Gatault, S ^a   Dendooven, A ^a   Riveau, G ^d   Colombel, J F ^e   Desreumaux, P ^a,f   Dubuquoy, L ^a   Capron, M ^a  

^a UNIVERSITÉ DE LILLE   (France)

^b CAIRO UNIVERSITY   (Egypt)

^c Intestinal Biotech Development   (France)

^d UNIV LILLE   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; INTERLEUKIN 13; INTERLEUKIN 5; P28GST PROTEIN; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; HELMINTH PROTEIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SIGLEC5 PROTEIN, MOUSE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; EOSINOPHIL; FEMALE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION PREVENTION; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCHISTOSOMA; SCHISTOSOMIASIS; SPLEEN CELL; STOMACH PROTECTION; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL MOTION; CHEMICALLY INDUCED; CHEMISTRY; COLON; DEFICIENCY; DISEASE MODEL; IMMUNIZATION; IMMUNOLOGY; INTESTINE MUCOSA; MALE; MOUSE; PARASITOLOGY; PATHOLOGY; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SPRAGUE DAWLEY RAT; TH1 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL MOVEMENT; COLITIS; COLON; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; GLUTATHIONE TRANSFERASE; HELMINTH PROTEINS; IMMUNIZATION; INTERLEUKIN-13; INTERLEUKIN-5; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TH1 CELLS; TH2 CELLS; TRINITROBENZENESULFONIC ACID;

EID: 84961771274     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2015.62     Document Type: Article

References (46)

1. Ng S.C, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 62, 630-649 (2013).
2. Wammes L, Mpairwe H, Elliott A.M, & Yazdanbakhsh M. Helminth therapy or elimination: epidemiological, immunological, and clinical considerations. Lancet Infect. Dis. 14, 1150-1162 (2014).
3. Weinstock J.V, & Elliott D.E. Helminths and the IBD hygiene hypothesis. Inflamm. Bowel Dis. 15, 128-133 (2009).
4. Strober W, & Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 140, 1756-1767 (2011).
5. Gause, W.C., Wynn T.A, & Allen J.E. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat. Rev. Immunol. 13, 607-614 (2013).
6. Mishra P.K, Palma M, Bleich D, Loke P, & Gause W.C. Systemic impact of intestinal helminth infections. Mucosal Immunol. 7, 753-762 (2014).
7. Nussbaum J.C, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 502, 245-248 (2013).
8. Maizels R.M, et al. Helminth parasites-masters of regulation. Immunol. Rev. 201, 89-116 (2004).
9. Maizels R.M, McSorley H.J, & Smyth D.J. Helminths in the hygiene hypothesis: sooner or later?. Clin. Exp. Immunol. 177, 38-46 (2014).
10. Brunet L.R, Dunne D.W, & Pearce E.J. Cytokine interaction and immune responses during Schistosoma mansoni infection. Parasitol. Today. 14, 422-427 (1998).
11. Brunet L.R, Finkelman F.D, Cheever A.W, Kopf M.A, & Pearce E.J. IL-4 protects against TNF-Alpha-mediated cachexia and death during acute schistosomiasis. J. Immunol. 159, 777-785 (1997).
12. Herbert D.R, et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity. 20, 623-635 (2004).
13. Cooke A, et al. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol. 21, 169-176 (1999).
14. Kuijk L.M, et al. Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Mol. Immunol. 51, 210-218 (2012).
15. Moreels T.G, et al. Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut. 53, 99-107 (2004).
16. Everts B, et al. Schistosome-derived omega-1 drives Th2 polarization by suppressing protein synthesis following internalization by the mannose receptor. J. Exp. Med. 209, 1753-1767. S1751 (2012).
17. Heylen, M, et al. Of worms, mice andman: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacol. Ther. 143, 153-167 (2014).
18. Balloul J.M, et al. Molecular cloning of a protective antigen of schistosomes. Nature. 326, 149-153 (1987).
19. Johnson K.A, et al. Crystal structure of the 28 kDa glutathione S-Transferase from Schistosoma haematobium. Biochemistry. 42, 10084-10094 (2003).
20. Boulanger D, et al. Vaccine potential of a recombinant glutathione S-Transferase cloned from Schistosoma haematobium in primates experimentally infected with anhomologous challenge.Vaccine 17, 319-326(1999).
21. Lebens M, et al. A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine. 21, 514-520 (2003).
22. Sun J.B, et al. Intranasal administration of a Schistosoma mansoni glutathione S-Transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. J. Immunol. 163, 1045-1052 (1999).
23. Capron A, Riveau G, Capron M, & Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol. 21, 143-149 (2005).
24. Riveau G, et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl. Trop. Dis. 6, e1704 (2012).
25. Khan C.M, et al. Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-Transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. Proc. Natl. Acad. Sci. USA. 91, 11261-11265 (1994).
26. Mielcarek N, et al. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16, 454-457 (1998).
27. Renauld-Mongenie G, et al. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc. Natl. Acad. Sci. USA. 93, 7944-7949 (1996).
28. Wirtz S, Neufert C, Weigmann B, & Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2, 541-546 (2007).
29. Zimmermann N, et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy. 63, 1156-1163 (2008).
30. Weinstock J.V, & Elliott D.E. Translatability of helminth therapy in inflammatory bowel diseases. Int. J. Parasitol. 43, 245-251 (2012).
31. Weinstock J.V, & Elliott D.E. Helminth infections decrease host susceptibility to immune-mediated diseases. J. Immunol. 193, 3239-3247 (2014).
32. Jouvin M.H, & Kinet J.P. Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J. AllergyClin. Immunol. 130, 3-10 (2012).
33. McSorley H.J, Hewitson J.P, & Maizels R.M. Immunomodulation by helminth parasites: defining mechanisms and mediators. Int. J. Parasitol. 43, 301-310 (2013).
34. de Jesus A.R, et al. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J. Infect. Dis. 185, 98-105 (2012).
35. Joseph S, et al. Cytokine production in whole blood cultures from a fishing community in an area of high endemicity for Schistosoma mansoni in Uganda: the differential effect of parasite worm and egg antigens. Infect. Immun. 72, 728-734 (2004).
36. Malaquias L.C, et al. Cytokine regulation of human immune response to Schistosoma mansoni: analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. Scand. J. Immunol. 46, 393-398 (1997).
37. Korsholm K.S, Petersen R.V, Agger E.M, & Andersen P. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology. 129, 75-86 (2010).
38. Rosenberg H.F, Dyer K.D, & Foster P.S. Eosinophils: changing perspectives in health and disease. Nat. Rev. Immunol. 13, 9-22 (2013).
39. Jung Y, & Rothenberg M.E. Roles and regulation of gastrointestinal eosinophils in immunity and disease. J. Immunol. 193, 999-1005 (2014).
40. Hogan S.P, Waddell A, & Fulkerson P.C. Eosinophils in infection and intestinal immunity. Curr. Opin. Gastroenterol. 29, 7-14 (2013).
41. Chu V.T, et al. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity. 40, 582-593 (2014).
42. Masterson J.C, et al. Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis. Gut pii: gutjnl-2014-306998 (2014); doi: 10.1136/gutjnl-2014-306998.
43. Wu D, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 332, 243-247 (2011).
44. Wallace J.L, MacNaughton W.K, Morris G.P, & Beck P.L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology. 96, 29-36 (1989).
45. Ameho C.K, et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut. 41, 487-493 (1997).
46. Arantes-Costa F, et al. Effects of residual oil fly ash (ROFA) in mice with chronic allergicpulmonary inflammation. Toxicol. Pathol. 36, 680-686 (2008).